Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
ZIDOVUDINE
ViiV Healthcare UK Ltd
J05AF01
ZIDOVUDINE
100 mg/10ml
Oral Solution
Product subject to prescription which may not be renewed (A)
Nucleoside and nucleotide reverse transcriptase inhibitors
Authorised
2011-09-30
Retrovir 100 MG / 10 ML ORAL SOLUTION ZIDOVUDINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness seem to be the same as yours. IF YOU GET ANY SIDE EFFECTS TALK TO YOUR DOCTOR OR PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. See section 4. What is in this leaflet 1 WHAT RETROVIR IS AND WHAT IT IS USED FOR 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE RETROVIR 3 HOW TO TAKE RETROVIR 4 POSSIBLE SIDE EFFECTS 5 HOW TO STORE RETROVIR 6 CONTENTS OF THE PACK AND OTHER INFORMATION RETROVIR IS USED TO TREAT HIV (HUMAN IMMUNODEFICIENCY VIRUS) INFECTION. The active ingredient in Retrovir is zidovudine. Retrovir is a type of medicine known as an anti-retroviral. It belongs to a group of medicines called _nucleoside analogue reverse _ _transcriptase inhibitors (NRTIs)_. Retrovir does not get rid of HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. Retrovir also increases the _CD4 cell count_ in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection. Retrovir is used, in combination with other medicines (‘combination therapy’), to treat HIV in adults and children. To control your HIV infection, and to stop your illness getting worse, you must keep taking all your medicines. If you’re pregnant, your doctor may want you to take Retrovir, to help prevent you passing HIV on to your unborn baby. After the birth, your baby may be given Retrovir to help prevent it from getting infected with HIV. HIV infection is spread by sexual contact with someone who’s got the infection, or by transfer of infected blood (for example, by sharing injection needles). Don’t take Retrovir: • IF YOU’RE ALLER Прочетете целия документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Retrovir 100 mg/10 ml oral solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 10 ml of solution contains 100 mg zidovudine. 10 ml of solution contains 6.4 g of maltitol For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Retrovir 100 mg/10ml oral solution/syrup A clear, pale yellow, strawberry-flavoured, sugar-free oral solution. The pack contains an oral-dosing syringe which should be fitted to the bottle before use. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Retrovir oral formulations are indicated in anti-retroviral combination therapy for Human Immunodeficiency Virus (HIV) infected adults and children. Retrovir chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Retrovir should be prescribed by physicians who are experienced in the treatment of HIV infection. _Dosage in adults and adolescents weighing at least 30 kg:_ The usual recommended dose of Retrovir in combination with other anti-retroviral agents is 250 or 300 mg twice daily. _Dosage in children:_ Retrovir 100 mg capsules are also available for use in children. _Children weighing at_ _least_ _9 kg and less than 30 kg:_ The recommended dose of Retrovir is 9 mg/kg twice daily in combination with other antiretroviral agents. The maximum dosage should not exceed 300 mg twice daily. _Children weighing at_ _least_ _4 kg and less than 9 kg:_ The recommended dose of Retrovir is 12 mg/kg twice daily in combination with other antiretroviral agents. Available data are insufficient to propose specific dosage recommendations for children weighing less than 4 kg_ (See_ _below -maternal foetal transmission and section 5.2)._ _Dosage in the prevention of_ _maternal-foetal_ _transmission:_ Pregnant women (over 14 weeks of gestation) should be given 500 mg/day orally (100 mg Прочетете целия документ